About
Science
Publications
Team
News
Careers
Contact us
inWhite
tw_white-black
MoreMenu
CloseWhite
About
Science
Publications
Team
News
Careers
Contact us
inWhite
tw_white-black
News
Asgard Therapeutics’ study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108
Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage
Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology
Asgard Therapeutics to present positive in vivo efficacy data with AT-108 as monotherapy at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Asgard Therapeutics highlighted at the Labiotech article “Investors Flock to Startups Reprogramming Cell Therapies”
Posted 25 November, 2021